共 50 条
- [2] Assessment of safety and activity in an expanded phase 1 study of MM-302, a HER2-targeted liposomal doxorubicin, in patients with advanced HER2-positive (HER2+) breast cancerCANCER RESEARCH, 2013, 73Munster, P.Krop, I. E.Miller, K.Dhindsa, N.Niyijiza, C.Nielsen, U.Odueyungbo, A.Rajarethinam, A.Marande, M.Campbell, K.Geretti, E.Reynolds, J. G.Hendriks, B. S.Wickham, T.Moyo, V.LoRusso, P.
- [3] A phase I study of MM-302, a HER2-targeted PEGylated liposomal doxorubicin, in patients with HER2+metastatic breast cancerCANCER RESEARCH, 2015, 75LoRusso, PatriciaKrop, IanMiller, KathyMa, CynthiaSiegel, Barry A.Shields, Anthony F.Molnar, IstvanWickham, ThomasReynolds, JosephCampbell, KarenHendriks, BartMcClure, TyMoyo, VictorMunster, Pamela
- [4] Safety and pharmacokinetics of MM-302, a HER2-targeted antibody–liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation studyBritish Journal of Cancer, 2018, 119 : 1086 - 1093Pamela MunsterIan E. KropPatricia LoRussoCynthia MaBarry A. SiegelAnthony F. ShieldsIstván MolnárThomas J. WickhamJoseph ReynoldsKaren CampbellBart S. HendriksBambang S. AdiwijayaElena GerettiVictor MoyoKathy D. Miller
- [5] Safety and pharmacokinetics of MM-302, a HER2-targeted antibody-liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation studyBRITISH JOURNAL OF CANCER, 2018, 119 (09) : 1086 - 1093Munster, PamelaKrop, Ian E.LoRusso, PatriciaMa, CynthiaSiegel, Barry A.Shields, Anthony F.Molnar, IstvanWickham, Thomas J.Reynolds, JosephCampbell, KarenHendriks, Bart S.Adiwijaya, Bambang S.Geretti, ElenaMoyo, VictorMiller, Kathy D.
- [6] MM-302, HER2-targeted liposomal doxorubicin, does not impair cardiomyocyte function in vitroCANCER RESEARCH, 2011, 71Reynolds, JosephKlinz, StephanLeonard, ShannonGeretti, ElenaLee, HelenEckelhofer, IsabelleGaddy, DanielHendriks, BartWickham, Tom
- [7] Effect of pre-treatment with cyclophosphamide on MM-302 (HER2-targeted liposomal doxorubicin) deposition in HER2-positive metastatic breast cancer patients assessed by 64Cu-MM-302 PET/CTCANCER RESEARCH, 2015, 75Miller, KathyLoRusso, Patricia M.Munster, PamelaKrop, IanMa, CynthiaLee, HelenReynolds, JoeCampbell, KarenMoyo, VictorHendriks, BartWickham, ThomasSiegel, Barry A.Shields, Anthony F.
- [8] HER2-targeted PEGylated liposomal doxorubicin (MM-302) efficiently targets the HER2 intermediate cell population in vitro and in vivoCANCER RESEARCH, 2016, 76Geretti, ElenaEspelin, ChristopherAdiwijaya, BambangDumont, NancyComa, SilviaKoncki, ZacharyMinh PhamGarcia, GabrielaBloom, TroyRimkunas, VictoriaReynolds, JoeCampbell, KarenMoyo, VictorMolnar, IstvanLoRusso, PatriciaKrop, IanMiller, KathyMa, CynthiaMunster, PamelaWickham, Thomas
- [9] MM-302, a HER2-targeted liposomal doxorubicin, shows binding/uptake and efficacy in HER2 2+cells and xenograft modelsCANCER RESEARCH, 2011, 71Klinz, StephanEckelhofer, IsabelleGaddy, DanielGeretti, ElenaHendriks, BartLee, HelenLeonard, ShannonReynolds, JoeWickham, Tom
- [10] In vitro and in vivo activity of HER2-targeted antibody-liposomal doxorubicin conjugate MM-302 in HER2-intermediate tumorsCANCER RESEARCH, 2017, 77Geretti, E.Espelin, C.Adiwijaya, B.Coma, S.Koncki, Z.Sumner, P.Dumont, N.Garcia, G.Bloom, T.Janovsky, J.Reynolds, J.Campbell, K.Moyo, V.Molnar, I.LoRusso, P.Krop, I.Miller, K.Ma, C.Munster, P.Wickham, T.